Scarica l'app Stockscreener
27.44
0.62%
-0.17
Agios Pharmaceuticals Inc Borsa (AGIO) Ultime notizie
Bull Bear: Does ProShares Trust ProShares Ultra Energy stock benefit from AI growthTrade Analysis Report & Intraday High Probability Alerts - baoquankhu1.vn
Arrowhead gains, Agios drops as drug developers end 2025 up 34% - BioWorld MedTech
Recap Report: Is Agios Pharmaceuticals Inc stock showing strong momentumDividend Hike & Low Drawdown Investment Ideas - baoquankhu1.vn
Swing Trade: Is Agios Pharmaceuticals Inc stock overvalued or fairly pricedMarket Risk Report & Weekly Watchlist for Hot Stocks - baoquankhu1.vn
Aug Summary: Does Agios Pharmaceuticals Inc have a competitive edge2025 Support & Resistance & Free High Accuracy Swing Entry Alerts - baoquankhu1.vn
Agios to Host Fourth Quarter and Full Year 2025 Financial Results Conference Call and Webcast on February 12 at 8:00 a.m. ET - marketscreener.com
Agios to Host Fourth Quarter and Full Year 2025 Financial Results Conference Call and Webcast on February 12 at 8:00 a.m. ET - GlobeNewswire Inc.
BofA Securities Maintains Agios Pharmaceuticals(AGIO.US) With Buy Rating, Maintains Target Price $35 - 富途牛牛
Sickle Cell Disease Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | BRL Medicine, Oryzon Genomics, GlaxoSmithKline, Agios Pharma, Beam Therapeutics, Graphite Bio, Roche - Barchart.com
Analysts Offer Insights on Healthcare Companies: Cardinal Health (CAH), Agios Pharma (AGIO) and Henry Schein (HSIC) - The Globe and Mail
Is Agios Pharmaceuticals (AGIO) Offering A Compelling Entry Point After Recent Share Price Swings - Yahoo Finance
Agios Pharmaceuticals, Inc. (AGIO): A Bull Case Theory - Finviz
Pharma News: Will Agios Pharmaceuticals Inc face regulatory challengesWeekly Gains Report & Daily Momentum Trading Reports - baoquankhu1.vn
What is Agios Pharmaceuticals Inc.’s market positionQuarterly Growth Report & Fast Moving Trade Plans - bollywoodhelpline.com
Q2 EPS Estimate for Agios Pharmaceuticals Boosted by Analyst - MarketBeat
A Look At Agios Pharmaceuticals (AGIO) Valuation After AQVESME FDA Approval And Commercial Launch - Sahm
Agios Pharmaceuticals CEO Goff sells $506,663 in stock By Investing.com - Investing.com Nigeria
Is Agios’ AQVESME Thalassemia Launch and Sickle Cell Pathway Altering The Investment Case For Agios Pharmaceuticals (AGIO)? - Sahm
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Sectors Review: Is Agios Pharmaceuticals Inc stock influenced by commodity pricesEarnings Performance Report & Accurate Entry and Exit Point Alerts - baoquankhu1.vn
Rep. Gilbert Ray Cisneros, Jr. Purchases Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - MarketBeat
Agios Pharmaceuticals Touts 2026 Growth Plan at JPM: Acvezmi Launch, SCD Data, Expense Discipline - MarketBeat
Agios Pharmaceuticals outlines 2026 strategic priorities - Yahoo Finance
Agios Pharmaceuticals, Inc. (AGIO) Stock Analysis: Exploring a 29.77% Potential Upside in Biotechnology - DirectorsTalk Interviews
Weekly Recap: How Agios Pharmaceuticals Inc. stock valuations compare to rivalsWatch List & Accurate Buy Signal Notifications - Bộ Nội Vụ
Sickle Cell Disease Treatment Market is Thriving Worldwide | - openPR.com
Agios begins U.S. launch of thalassemia drug following FDA approval By Investing.com - Investing.com Canada
Ideas Watch: Is Agios Pharmaceuticals Inc stock good for income investorsJuly 2025 Update & High Accuracy Trade Signal Alerts - baoquankhu1.vn
Agios begins U.S. launch of thalassemia drug following FDA approval - Investing.com
Agios Pharmaceuticals Outlines 2026 Strategic Priorities and Milestones - TradingView — Track All Markets
Agios Outlines 2026 Strategic Priorities and Key Milestones to Accelerate Rare Disease Portfolio Growth - The Manila Times
Agios Outlines 2026 Strategic Priorities and Key Milestones to Accelerate Rare Disease ... - caledonianrecord.com
New anemia pill and sickle cell trials set up big year in rare disease care - Stock Titan
Published on: 2026-01-11 10:51:52 - ulpravda.ru
Peregrine Capital Management LLC Makes New $6.54 Million Investment in Agios Pharmaceuticals, Inc. $AGIO - MarketBeat
How Agios Pharmaceuticals Inc. stock performs in rate cut cycles2025 Big Picture & Technical Pattern Based Buy Signals - ulpravda.ru
Agios Pharmaceuticals plunges as Phase 3 sickle cell results deliver a mixed picture - MSN
(AGIO) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
AGIO ALERT- Levi & Korsinsky Has Commenced an Investigation on Behalf of Agios Pharmaceuticals, Inc. Shareholders Who Lost Money - ACCESS Newswire
What Wall Street predicts for Agios Pharmaceuticals Inc. stock priceJuly 2025 Patterns & AI Forecasted Entry and Exit Points - ulpravda.ru
What RSI levels show for Agios Pharmaceuticals Inc. (8AP) stockEarnings Recap Summary & Detailed Earnings Play Strategies - Улправда
Market Review: How Agios Pharmaceuticals Inc. stock responds to policy changesJuly 2025 Drop Watch & Technical Buy Zone Confirmation - Улправда
Why Agios Pharmaceuticals Inc. stock is seen as undervalued2025 Trade Ideas & High Return Trade Opportunity Guides - Улправда
How Agios Pharmaceuticals Inc. stock reacts to Fed rate cutsJuly 2025 Price Swings & Stepwise Trade Signal Guides - ulpravda.ru
How Agios Pharmaceuticals Inc. stock performs after earnings2025 Market WrapUp & Verified High Yield Trade Plans - Улправда
What Catalysts Are Rewriting The Story For Agios Pharmaceuticals (AGIO)? - Yahoo Finance
Milanova, Agios Pharmaceuticals CCO, sells $77k in stock By Investing.com - Investing.com India
Milanova, Agios Pharmaceuticals CCO, sells $77k in stock - Investing.com
Bank of America Securities Reaffirms Their Buy Rating on Agios Pharma (AGIO) - The Globe and Mail
Here's why shares in Agios Pharmaceuticals popped today - MSN
JP Morgan Raises Price Target for Agios Pharmaceuticals (AGIO) t - GuruFocus
Agios Pharmaceuticals, Inc. Being Investigated on Behalf of Agios Pharmaceuticals, Inc. Investors. Contact Levi & Korsinsky For Details - ACCESS Newswire
1.27%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):